Hot Life Science Investor Mandate 3: VC Fund Looking Opportunistically in Life Sciences

4 Sep

A VC fund with offices throughout the Unites States seeks to invest in early to late stage life science companies. The firm is investing out of its first fund of $125M which closed in late 2013. The firm can allocate up to $5M in equity per company. The firm prefers to invest in US-based companies but will consider truly exceptional opportunities around the world. The firm is actively seeking new investment opportunities. 

The firm is currently seeking to invest in biotech therapeutics, diagnostics, pharmaceuticals, and medical devices. For therapeutics, the firm looks for small molecules and biologics and is open to biosimilars and all indications including orphan indications. The firm will consider products in from preclinical to the late stages of clinical trials. For medical devices, the firm will invest as early as proof of concept. The firm is opportunistic in terms of subsectors and indications. 

The firm’s investment model differs from a traditional venture capital approach. The firm wants to back entrepreneurs who are already positioning themselves with potential acquirers. Most importantly, the firm is predicated on identifying exit opportunities and strategic corporate partners even before the investment is made. The firm requires a board seat in each portfolio company when they lead the investment. The firm seeks a strong and experienced management team.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: